基石药业：CS2009 II期临床试验于澳大利亚完成首例患者入组

Core Insights - The company announced the completion of the first patient enrollment in the global multicenter Phase II clinical trial for its core pipeline product CS2009, a tri-specific antibody targeting PD-1/VEGF/CTLA-4 [1] - The trial is actively enrolling patients in Australia and China, with plans to expand to the United States in the future [1] - The Phase II trial employs a multi-cohort parallel expansion design, covering 15 cohorts and various solid tumor indications, focusing on evaluating the safety, tolerability, pharmacokinetics/pharmacodynamics (PK/PD) characteristics, and efficacy of CS2009 as a monotherapy and in combination therapy [1]